2Falagas ME,Kopterides P.Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa:a sys-tematic review of the literature [ J ].J Hasp Infect,2006,64(1):7-15.
8[1]Seifert H,Stefanik D,Wisplinghoff H.Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates.J Antimicrob Chemother,2006,58(5):1099-1100.
1Wyeth Pharmaceuticals Inc. Philadelphia P. Lable of TYGACIL (tigecycline) for intravenous use[EB/OL], http: ffwaccessdatafd- agov/drugsatfda _ docs/label/2013 / 021821 -sO26s031 lblpdf , 2013- 09/2015 -07 -06.
2Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug- resistant Gram-negative pathogens: current and emerging therapeutic approaches [ J ]. Expert Opinion on Pharmacotherapy, 2014, 15 (10) : 1351-1370.
3Giamarellou H. Muhidrug-resistant Gram-negative bacteria: how to treat and for how long[ J]. International Journal of Antimicrobial A- gents,2010,36( Suppl 2) : $50-$54.
4Hanberger H, Giske CG, Giamarellou H. When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock[ J]. Current Infectious Disease Reports,2011,13 (5) : 416-425.
5Poulakou G, Kontopidou FV, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens [J]. Journal of Infection, 2009,58 (4) : 273 -284.
6Morfin-Otero R, Dowzieky MJ. Changes in MIC within a global collec- tion of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009 [ J]. Clinical Thera- peutics,2012,34 ( 1 ) : 101-112.
7Kanj SS, Whitelaw A, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 [ J]. International Journal of Antimicrobial Agents, 2014,43 ( 2 ) : 170-178.
8Sun JR,Perng CL,Lin JC,et al. AdeRS combination codes differenti- ate the response to efflux pump inhibitors in tigecycline-resistant iso- lates of extensively drug-resistant Aeinetobaeter baumannii [ J ]. Eu- ropean Journal of Clinical Microbiology & Infectious Diseases : Offi- cial Publication of the European Society of Clinical Microbiology, 2014,33 (12) : 2141-2147.
9Pallotto C, Fiorio M, D~Avolio A ,et al. Cerebrospinal fluid penetration of tigecycline[J]. Scandinavian journal of Infectious Diseases,2014, 46( 1 ) :69-72.
10Ray L, Levasseur K, Nicolau DP,et al. Cerebral spinal fluid penetra- tion of tigecycline in a patient with Acinetobacter baumannii cerebri- tis[J]. Annals of Pharmacotherapy,2010,44 ( 3 ) :582-586.
